title: The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
abstract: There is no established standard salvage chemotherapy in the second-line setting for patients with advanced gastric cancer (AGC) pre-treated with platinum and taxane-based chemotherapy. Our study aims to evaluate the safety and efficacy of FOLFIRI regimen (irinotecan with leucovorin and bolus and continuous infusion with 5-fluorouracil) as a salvage chemotherapy regimen in patients with AGC. Medical records of 97 patients with AGC who received second-line FOLFIRI regimen between March 2006 and February 2011 were examined. Complete and partial responses were observed in 3 (3.1%) and 23 (23.7%) patients, respectively. The median time to progression (TTP) was 3.5 months (95% CI: 2.4-4.6) and the median overall survival (OS) was 10.5 months (95% CI: 8.8-12.2). The most common observed grade 3/4 toxicities were neutropenia (23.7%), diarrhea (6.2%), and stomatitis (5.2%). FOLFIRI regimen is safe and effective in the second-line treatment of AGC patients pre-treated with cisplatin and taxanes.
authors.affiliation: Bakırkoy Dr Sadl Konuk Training and Research Hospital, Department of Medical Oncology, Istanbul, Turkey. aosmankaya@gmail.com
authors.forename: Ali Osman
authors.initials: AO
authors.lastname: Kaya
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Isıkdogan
authors.forename: Necati
authors.initials: N
authors.lastname: Alkis
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
authors.forename: Fulden
authors.initials: F
authors.lastname: Yumuk
authors.forename: Burcin
authors.initials: B
authors.lastname: Budakoglu
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Veli
authors.initials: V
authors.lastname: Berk
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.forename: Ali
authors.initials: A
authors.lastname: Inal
authors.forename: Erkan
authors.initials: E
authors.lastname: Arpacı
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009503:Neutropenia / Q000139:chemically induced; D017671:Platinum Compounds / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D043823:Taxoids / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D017671:Platinum Compounds; D043823:Taxoids; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin